EGFR and neoplasm: Drugs targeting EGFR, e.g., afatinib, which irreversibly inhibits HER2, HER4, and EGFR kinases [4]; Erbitux, a chimeric (mouse/human) anti-EGFR monoclonal antibody (mAb) [5]; or erlotinib that binds reversibly to the receptor’s ATP binding site, have activity in different tumor types.